Alzheimer and Lithium

Lithium, a well-established therapeutic option for the management of bipolar disorder and major depression, has also been regarded as a neuroprotective agent and a candidate drug for disease-modification in certain neurodegenerative disorders like e.g. Alzheimer's disease. Lithium inhibits the phosphorylation of glycogen-synthase-kinase 3-alpha and -beta (GSK3A and GSK3B), which are related to amyloid precursor protein processing and tau hyperphosphorylation in pathological conditions, respectively. Microdose lithium treatment stabilizes the cognitive impairment in AD patients.

Statistics

Interactions15Proteins/Genes5Chemical compounds/drugs1
Biological Process(GO)0Phenotype2

Biological Process(GO)

Chemical compounds/drugs

Lithium6